anti-PSMA CAR T-cell therapy (Memorial Sloan-Kettering Cancer Center)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-PSMA CAR T-cell therapy (Memorial Sloan-Kettering Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsT lymphocytes stimulantsImmunostimulants
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A